Business
PCI Pharma Services Enters Next Phase of Growth With Strategic Investment from Bain Capital, Kohlberg, and Mubadala
PHILADELPHIA, July 14, 2025--PCI Pharma Services ("PCI" or the "Company"), a world-leading global contract development and manufacturing organization (CDMO) focused on innovative biotherapies, today announced that it received a strategic investment co-led by Bain Capital and existing lead investor Kohlberg, and supported with significant reinvestment by Mubadala Investment Company ("Mubadala"). Partners Group will also continue to support the Company with a minority investment. Financial terms o
About this update from Partners Group Holding Ag
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":267,"url":"https://media.zenfs.com/en/business-wire.com/86f7d13b1a63f37c09fc902a33cdbe80"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FELTNC5jY5jmUwOEZzDxpw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUzNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/86f7d13b1a63f37c09fc902a33cdbe80","width":480,"height":267}},"lazy":false},{"type":"text","content":"Investment Will Accelerate PCI’s Leading Position in CDMO, Delivering Life-Changing Therapies to Patients","length":105,"tagName":"p","attribs":{}},{"type":"text","content":"Transaction Includes Continued Investment from Partners Group","length":61,"tagName":"p","attribs":{}},{"type":"text","content":"PHILADELPHIA, July 14, 2025--(BUSINESS WIRE)--PCI Pharma Services ("PCI" or the "Company"), a world-leading global contract development and manufacturing organization (CDMO) focused on innovative biotherapies, today announced that it received a strategic investment co-led by Bain Capital and existing lead investor Kohlberg, and supported with significant reinvestment by Mubadala Investment Company ("Mubadala"). Partners Group will also continue to support the Company with a minority investment. Financial terms of the private transaction were not disclosed.","length":592,"tagName":"p"},{"type":"text","content":"Headquartered in Philadelphia, Pennsylvania, PCI provides clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 450 successful product launches over the last five years and over 50 years in pharmaceutical services helping bring to life innovation to improve patient access and outcomes.","length":473,"tagName":"p"},{"type":"text","content":"Kohlberg and Mubadala, both of which initially invested in PCI in 2020, and Bain Capital are partnering with PCI's management team, led by Chief Executive Officer Salim Haffar, to accelerate the Company’s growth trajectory, build upon its strong customer service experience, and further enable PCI clients to bring life-changing biopharmaceutical therapies to market. PCI will pri...